Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) Target Price at $29.83

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been given an average rating of “Moderate Buy” by the six brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $29.83.

A number of equities analysts have recently weighed in on TGTX shares. HC Wainwright upped their price target on shares of TG Therapeutics from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. LADENBURG THALM/SH SH increased their target price on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Finally, JPMorgan Chase & Co. reissued an “overweight” rating and set a $25.00 target price on shares of TG Therapeutics in a research report on Thursday, April 18th.

Institutional Investors Weigh In On TG Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Pingora Partners LLC bought a new stake in shares of TG Therapeutics in the fourth quarter valued at about $27,000. PNC Financial Services Group Inc. lifted its stake in shares of TG Therapeutics by 131.7% in the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,014 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in shares of TG Therapeutics in the first quarter valued at about $58,000. Anchor Investment Management LLC bought a new stake in shares of TG Therapeutics in the fourth quarter valued at about $80,000. Finally, Lazard Asset Management LLC bought a new stake in shares of TG Therapeutics in the first quarter valued at about $91,000. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Price Performance

TGTX opened at $18.79 on Friday. The stock has a fifty day moving average of $16.81 and a 200-day moving average of $16.11. The firm has a market capitalization of $2.90 billion, a P/E ratio of 81.70 and a beta of 2.23. TG Therapeutics has a 12-month low of $6.46 and a 12-month high of $26.95. The company has a quick ratio of 2.84, a current ratio of 3.62 and a debt-to-equity ratio of 0.63.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). TG Therapeutics had a return on equity of 31.34% and a net margin of 14.24%. The company had revenue of $63.47 million during the quarter, compared to analyst estimates of $54.60 million. During the same period last year, the company posted ($0.28) earnings per share. The company’s revenue was up 713.5% compared to the same quarter last year. Equities analysts forecast that TG Therapeutics will post -0.01 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.